Abstract:
A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy has a microstructure including equiaxed Mg-rich solid solution-phase grains having an average grain diameter of less than or equal to 5 microns and second-phase precipitates in grain boundaries between the equiaxed Mg-rich solid solution-phase grains. The beta-phase precipitates have an average longest dimension of 0.5 micron or less. The microstructure can be produced by one or more equal-channel high-strain processes.
Abstract:
A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy has a microstructure including equiaxed Mg-rich solid solution-phase grains having an average grain diameter of less than or equal to 5 microns and second-phase precipitates in grain boundaries between the equiaxed Mg-rich solid solution-phase grains. The beta-phase precipitates have an average longest dimension of 0.5 micron or less. The microstructure can be produced by one or more equal-channel high-strain processes.
Abstract:
A medical device for reducing the volume of a left atrial appendage (LAA) may include an elongate shaft having a distal portion, and a volume-reducing means expandable from a collapsed to an expanded state, the volume-reducing means being releasably attached to the distal portion. The volume-reducing means may include an actuatable frame and an impermeable covering disposed over the frame. The volume-reducing means may be sized to fit within the LAA in the expanded state while maintaining an open fluid flow path from a distal region through the ostium of the LAA. A medical device may include a second volume-reducing means to be placed within and substantially occlude a distalmost region of the LAA. A method may include inserting a volume-reducing means into the LAA, expanding the volume-reducing means, and positioning the volume-reducing means such that an open fluid flow path is maintained through an entire cycle of the heart.
Abstract:
A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy includes magnesium, between 7 and 8 weight percent aluminum, between 0.4 and 0.8 weight percent zinc, and between 0.05 and 0.8 weight percent manganese.
Abstract:
Provided are devices, systems and methods of selectively controlling air flow into one or more section of a patient's lungs. In particular, the devices may be valve devices having an inner lumen configured to transition between a first diameter and a second diameter smaller than the first diameter to control the airflow through the valve.
Abstract:
A medical device for reducing the volume of a left atrial appendage (LAA) may include an elongate shaft having a distal portion, and a volume-reducing means expandable from a collapsed to an expanded state, the volume-reducing means being releasably attached to the distal portion. The volume-reducing means may include an actuatable frame and an impermeable covering disposed over the frame. The volume-reducing means may be sized to fit within the LAA in the expanded state while maintaining an open fluid flow path from a distal region through the ostium of the LAA. A medical device may include a second volume-reducing means to be placed within and substantially occlude a distalmost region of the LAA. A method may include inserting a volume-reducing means into the LAA, expanding the volume-reducing means, and positioning the volume-reducing means such that an open fluid flow path is maintained through an entire cycle of the heart.
Abstract:
A bioerodible endoprosthesis includes a bioerodible magnesium alloy. The bioerodible magnesium alloy has a microstructure including equiaxed Mg-rich solid solution-phase grains having an average grain diameter of less than or equal to 5 microns and second-phase precipitates in grain boundaries between the equiaxed Mg-rich solid solution-phase grains. The beta-phase precipitates have an average longest dimension of 0.5 micron or less. The microstructure can be produced by one or more equal-channel high-strain processes.
Abstract:
A medical device for regulating fluid flow within one or more lungs of a patient is disclosed. The medical device includes an elongate tubular member, a first extension, a second extension, and a valve member. The elongate tubular member includes a first plurality of channels extending between a proximal and distal ends. The first and second extensions defines a second and third plurality of channels, respectively, each extending from the distal end of the elongate tubular member and configured for placement in a first and second passageway of a lung. The valve member operably couples to the elongate tubular member and is configured to transition between a first position and a second position. The valve member prevents fluid flow to first set of the first plurality of channels in the first position and prevents fluid flow to second set of the first plurality of channels in the second position.
Abstract:
A medical device for reducing the volume of a left atrial appendage (LAA) may include an elongate shaft having a distal portion, and a volume-reducing means expandable from a collapsed to an expanded state, the volume-reducing means being releasably attached to the distal portion. The volume-reducing means may include an actuatable frame and an impermeable covering disposed over the frame. The volume-reducing means may be sized to fit within the LAA in the expanded state while maintaining an open fluid flow path from a distal region through the ostium of the LAA. A medical device may include a second volume-reducing means to be placed within and substantially occlude a distalmost region of the LAA. A method may include inserting a volume-reducing means into the LAA, expanding the volume-reducing means, and positioning the volume-reducing means such that an open fluid flow path is maintained through an entire cycle of the heart.